Ionis Pharmaceuticals EBIT

The latest EBIT for IONS is $-210M as of June 2026. That compares with $-150B in the prior-year period — up 99.9% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Ionis Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, IONS's EBIT moved from $-150B to $-210M — a 99.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ionis Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, IONS currently prints $-210M for EBIT, while the sector average sits near $22B. That is roughly 100.9% below the sector mean. Large gaps often invite a closer look at Ionis Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-210M for IONS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting IONS's EBIT ($-210M), review year-over-year change from $-150B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.